Search results
Results from the WOW.Com Content Network
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide. [1] It is used either by itself or along with other antituberculosis medication. [1] It is taken by mouth. [1] Side effects are those of the underlying medications. [1] These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness ...
The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for tuberculosis. [8 ...
Rifampicin is used for the treatment of tuberculosis in combination with other antibiotics, such as pyrazinamide, isoniazid, and ethambutol. [10] For the treatment of tuberculosis, it is administered daily for at least six months. [11] Combination therapy is used to prevent the development of resistance and to shorten the length of treatment. [12]
Combination of; ethambutol: anti-tuberculosis medication: isoniazid: ... Side effects are those of the underlying medications. [1] Use may not be suitable in children ...
Isoniazid can be used alone or in combination with Rifampin for treatment of latent tuberculosis, or as part of a four-drug regimen for treatment of active tuberculosis. [27] The drug regimen typically requires daily or weekly oral administration for a period of three to nine months, often under Directly Observed Therapy (DOT) supervision. [27]
It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] As of 2019, it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. [2] It is taken by mouth. [3] Side effects may include trouble sleeping, weight gain, and rash.
Combination therapy may seem costlier than monotherapy in the short term, but when it is used appropriately, it causes significant savings: lower treatment failure rate, lower case-fatality ratios, fewer side-effects than monotherapy, slower development of resistance, and thus less money needed for the development of new drugs.